Topic: [ANN][ICO]ARNA Panacea — Token Sale is Closed - page 38. (Read 10969 times)
project with the concept that I really like, it will help many people to detect their illness earlier, so get handling with very fast, hopefully run very well, I like your idea, mission that will be useful for people, good luck
Great to see you again with cool design and bounty campaign! 
I would like to know how ARNA Panacea will be applied to ARNA BC?
I would like to know how ARNA Panacea will be applied to ARNA BC? Reserve indonesian translation and moderation
here my previous work
1. Cypher Mobile ANN thread : https://bitcointalksearch.org/topic/m.21835369
2. SexService.io ANN thread : https://bitcointalksearch.org/topic/m.21727643
3. SexService.io Bounty thread : https://bitcointalksearch.org/topic/m.21728259
4. SexService.io Web Wallet Translation https://wallet.sexservice.io/login/ for indonesian language
here my previous work
1. Cypher Mobile ANN thread : https://bitcointalksearch.org/topic/m.21835369
2. SexService.io ANN thread : https://bitcointalksearch.org/topic/m.21727643
3. SexService.io Bounty thread : https://bitcointalksearch.org/topic/m.21728259
4. SexService.io Web Wallet Translation https://wallet.sexservice.io/login/ for indonesian language
Hi!
Please check if it is still available here: https://bitcointalksearch.org/topic/bounty-arna-panacea-2nd-round-is-live-2181165
Thank you!
Reserve indonesian translation and moderation
here my previous work
1. Cypher Mobile ANN thread : https://bitcointalksearch.org/topic/m.21835369
2. SexService.io ANN thread : https://bitcointalksearch.org/topic/m.21727643
3. SexService.io Bounty thread : https://bitcointalksearch.org/topic/m.21728259
4. SexService.io Web Wallet Translation https://wallet.sexservice.io/login/ for indonesian language
here my previous work
1. Cypher Mobile ANN thread : https://bitcointalksearch.org/topic/m.21835369
2. SexService.io ANN thread : https://bitcointalksearch.org/topic/m.21727643
3. SexService.io Bounty thread : https://bitcointalksearch.org/topic/m.21728259
4. SexService.io Web Wallet Translation https://wallet.sexservice.io/login/ for indonesian language
reserved
Hi ARNA community!
Wow! A new video on our YouTube channel!.
It is an interview with Dr. Dmitry Kulish discussing ARNA Breast Cancer test and blockchain ecosystem ARNA Panacea.
Dmitry is an advisor of ARNA project, independent expert in the fields of strategic,
organizational and technological development of pharmaceutical products.
He holds PhD in Biology, has been a postdoc at Harvard Medical School.
Don't forget to like, share and subscribe!
Wow! A new video on our YouTube channel!.
It is an interview with Dr. Dmitry Kulish discussing ARNA Breast Cancer test and blockchain ecosystem ARNA Panacea.
Dmitry is an advisor of ARNA project, independent expert in the fields of strategic,
organizational and technological development of pharmaceutical products.
He holds PhD in Biology, has been a postdoc at Harvard Medical School.
Don't forget to like, share and subscribe!
ARNA Panacea — Blockchain Biotech Ecosystem inspired by 1st disruptive breast cancer test ARNA BC
BOUNTY CAMPAIGN
Pool: 0,75-1% from ICO amount. Activities: translation & moderation, signature & avatar, blogs & media, Twitter, Facebook, Bug.
Pool: 0,75-1% from ICO amount. Activities: translation & moderation, signature & avatar, blogs & media, Twitter, Facebook, Bug.
Useful Links
- Website
- White Paper
- Accounts on social media:Who we are?
ARNA Genomics is the innovative biotechnological company engaged in R&D and launching on market methods of oncological diseases early detection using blockchain-ecosystem ARNA Panacea.
ARNA Breast Cancer is the first test developed for early detection of breast cancer with a high-precision.
ARNA Panacea is a solution which provides to all interested participants in the cancer diagnosis market with a new way of accessing and interacting with the system for collecting and storing medical research data.
By using ARNA tokens, their holders will be able to access services and medical research data storage system for use in professional medical purposes, and to raise funds to begin new researches
Token Sale start: December 15, 2017
Token Sale end: February 10, 2018
To participate you should fill out the Crowdsale Waitlist on the ARNA Genomics WEBSITE.
Token distribution date: February 10, 2017
Token cost: 0.000266 ETH
Payment methods accepted: Ethereum (ETH)
Token sale target: 17890 ETH
Token Distribution Event:: 500,000,000 ARNATOKENS AND FUNDS
ROAD MAP
Team
EGOR MELNIKOV — Economist, experienced entrepreneur and manager. Participated in startups in different economy sectors in role of founder, co-founder and CEO: advertising and production business, international logistics, IT solutions integration for large-scale governmentally owned and private customers, was CEO of international telecom operator. Founder of ARNA Genomics – innovative biotechnology company which mission is to save lifes from cancer.
GEORGE NIKITIN — is a physicist by education (master, diploma with honors), worked in large international companies, as well as in private projects of private equity companies (telecom, subsoil use and real estate). He has extensive experience in operational management of various business areas and held senior management positions in a number of private and public companies.
ANATOLIY MELNIKOV — Having more than 40 years of experience in molecular biology and genetics, he is the author and co-author of more than 50 scientific articles. For 15 years he worked in various scientific laboratories and USA companies, before that in the Institute of Physics and Technology of the Russian Academy of Sciences. He graduated from the biological faculty of the Lomonosov Moscow State University.
ILYA SENECHKIN — Medical director in Sweetchild Group, Medical Advisor in MC Vitriolife, before that IVF Professional in MD Medical Group and scientific expert in Wageningen University in Netherlands.
SERGEY CHERNYSHEV — Branch of the Institute of Bioorganic Chemistry. Acad. M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Sciences, Pushchino. Specialization — molecular biology, biotechnology, genetic engineering. Area of scientific interests: regulation of gene expression, transcription, translation, molecular mechanisms of bacterial phage lysis.
MAGOMED CHATUEV — Software architect and developer. Has a big experience working with start-ups in the areas of e-commerce, PR & Marketing, finance, transportation, ERP development. Mainly focused on building SaaS, APIs & complex business processes automation. Had been working in international companies in Russia, Ireland, and Germany.
ALEXANDER MAZALETSKIY — Software Architect. Founder, CEO and Principal engineer in blockchain integrator Dicoiner (www.dicoiner.com) Founder and CEO in mobile development studio Zero Cool Team. 10 years experience in enterprise fintech software design and development.
SERGEY DOLGACHEV — Sergey is an entrepreneur and co-owner of several companies in the oilfield service, medicine and biotech. He graduated from the Faculty of Computational Mathematics and Cybernetics of the Moscow State University. Lomonosov, EMBA Higher School of Economics, studied at the Skolkovo Management School and graduate school of MGIMO.
VLADIMIR SAVANOVICH — Co-founder, Head of Investor Relations. Has a master’s degree in physics. During his professional experience, he worked in various business areas, mainly focusing on the active development of the contractual base of enterprises. He has experience in working in a Western consulting company, a resort development company, a Swiss investment fund and a Russian exploration company.ADVISORS
RON RIBITZKY, MD — brings to ARNA 30 years of cross-functional C-level experience in the converging Healthcare IT, Life-Sciences Informatics, and Precision Medicine. Prior to co-founding SPH Analytics, Dr. Ribitzky was Senior Healthcare Strategist at Intel, CIO at UMass Medical Center, VP Emerging Technologies at Eclipsys etc. He presented and led workshops on technology innovation and practice in industry events, public sector, and academia around the world. He held academic appointments at Harvard Medical School, University of Massachusetts Medical School, Emory School of Public Health, Weitzmann Institute of Science (Israel), Kigali Institute of Science & Technology, and Kigali Health Institute (Rwanda).
LINDA S. PELLICORE — graduated from Thomas Jefferson Medical College of Graduate Studies, Philadelphia, PA, with Ph.D.s in both Pharmacology and Toxicology, in 1987. She has 28 years expertise in New Drug Applications, Biologics, 510Ks, Food Additives and Dietary Supplements with the U.S. Food and Drug Administration, serving as the agency’s Senior Pharmacologist. She is a National Research Council Fellow, and is a member of numerous professional scientific societies.
WESLEY HYMER, PH.D — is an Emeritus Professor of Biochemistry at Penn State and winner of Penn State’s Faculty Scholar Medal for Life and Medical Sciences. He has countless academic papers, grants and including several patents that were developed when he was Director of Penn State’s Center for Cell Research, and one patent related to medical devices enabling targeted chemotherapy for cancers treatments. He collaborated with NASA on biotechnology and biomedical experiments in microgravity and developed unique electrophoresis experiments executed on board the U.S. Space Shuttle and microsatellites.
DMITRY KULISH — is an independent expert in the fields of strategic, organizational and technological development of pharmaceutical products. Dmitry holds a PhD in Biology, has been a postdoc at Harvard Medical School, earned MBA from the Wharton Business School, the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Moscow State Institute of Molecular Biology Lomonosov Moscow State University.
DMITRY GRIGORIEV — over 20 years of successful general management experience with a particular focus on business development and operational excellence. Сonstant over 5 years trend in business development and financial results improvement for large European integrated company with over 8 bln. USD in turnover and presence in over 15 countries. Has implemented several very successful business alliances strategies where the managed companies/clients have benefited from new distribution channels/partners reach.
PD DR. SOENKE BARTLING — Ph.D DR. MED, Board certified Radiologist, blockchain for research & healthcare / Open Science. Sönke has a tremendous background in neuroradiology at Hannover Medical School, Institute for Radiology and Interventional Therapy and other sound scientific organizations. Apart from that Sönke is well-known due to his activity in Web 2.0 for science in 00x, following by working on Blockchain for Science and Open Science (awarded in 2015, Germany land of ideas) concepts. He is author of more than 20 scientific publications, number of reviews, books and 6 patents. Holds various awards and is a member of governmental groups on radiology and tomography.
MIKHAIL GROUBMAN — joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.
MARINA SEKACHEVA — is a Doctor of Medical Sciences, a laureate of the Russian Government Prize in Science, a holder of post-doctoral degree in medicine of the Technical University of Munich, the Director of the Center for Personalized Oncology Sechenov OncoTarget, established as part of the Institute of Personalized Medicine in 2017.
ILYA N. CHISTYAKOV — MD., PhD, founder and CEO of the Preclinical Study Centre LLC, managing company of “Pharma Valley” biotechnological cluster – the only GLP OECD in Russia, an independent hybrid CRO specialized on conducting a full cycle of pharmacological development, manufacturing, preclinical and clinical studies of biotechnological, biosimilar and generic medicines.
ED KANALOSH — has more than 20 years of experience in biotech investments and strategic consulting. Partner of venture fund “Maxwell Biotech” (Moscow), director of consulting company Candesic (London). Edward is an acting head of Investment Service of Skolkovo fund, vice-president of Investment Bank “Trust” and consultant of New Jersey office of McKinsey company. His career has started in Bill and Melinda Gates Foundation Fund. MBA from Harvard Business School, MD with PhD.
ALEX KOSIK — is a successful serial technology entrepreneur. His focus is in Life Sciences, Medical Devices, FDA Compliance, Evidence-Based Medicine, Venture Capital and M&A. Alex is a recognized technology due diligence expert and senior analyst to several VC’s, angels, Gerson Lehrman Group and institutional investors. He co-founded multiple businesses himself, met Bill Gates, sold his “G1 Gravitonus workstations” to Forbes-100, and ranked 3rd by Becker’s Spine Review of “10 spine orthopedic surgeon tech entrepreneurs to know”
SERGEY BOROVSKIY — worked and lived in China since 1991. He has more than 20 years of experience in international management in China and Hong Kong. He held the positions of Chairman of the Board of Directors in various companies in China involved in international trade, investment and production. Since 2017, he was the General Manager of Sanju Environmental Protection (Hong Kong) Limited, coordinating the international projects of the controlling shareholder.
Learn more and get links to their profiles on social networks: ARNA TEAMUseful Links
Jump to: